Notice Of The Board Meeting
This is to inform you that the meeting of the Board of Directors is scheduled to be held on Saturday, the 27th day of May, 2017 inter-alia to consider and approve the audited financial results of the Company for the quarter and year ended 31 March 2017. Further, in terms of provisions of the Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the "Trading Window" of the Company shall remain closed from 21 May 2017 and... Certificate Under Clause 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Clause 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a certificate received from Practicing Company Secretary for the half year ended 31 March 2017 for the proper maintaining of Register of Members & records of the Company. Shareholding for the Period Ended March 31, 2017
IOL Chemicals & Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here Shareholding for the Period Ended March 31, 2017
IOL Chemicals & Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here Half Yearly Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations. 2015
Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclose herewith compliance certificate for the half year ended 31 March 2017 Statement Of Investor Complaints For The Quarter Ended 31 March 2017
Intimation under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Statement of Investor Complaints for the quarter ended 31 March 2017 Updates
Dear Sir, This is to inform you that the company has received EUGMP Certification from National Institute of Pharmacy and Nutrition, Hungary, for its product Ibuprofen, Lamotrigine, Metformin Hydrochloride confirming compliance with principals of Good Manufacturing Practices as provided by European Union Legislation. This will facilitate the company to expand its product portfolio in the European Market. This is for your information and record please. Outcome of Indepenent Directors Meeting
IOL Chemicals & Pharmaceuticals Ltd has informed BSE regarding Outcome of the meeting of Indepenent Directors held on February 11, 2017. Standalone Financial Results, Limited Review Report, Results Press Release for December 31, 2016
IOL Chemicals & Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 20163. Result Press Release for the period ended December 31, 2016 Board Meeting Intimation for Results & Closure of Trading Window
IOL Chemicals & Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled to be held on February 11, 2017, inter alia, to consider and approve the un-audited financial results of the Company for the quarter and nine months ended December 31, 2016.Further, in terms of provisions of the Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the "Trading Window" of the Company shall...